Join to View Full Profile
1515 Holcombe BlvdHouston, TX 77030
Phone+1 713-792-6161
Dr. Al-Atrash is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Education & Training
University of Texas Health Science Center at Houston/M D Anderson Cancer CenterFellowship, Hematology and Medical Oncology, 2005 - 2008
Cleveland Clinic FoundationResidency, Internal Medicine, 2002 - 2005
Texas College of Osteopathic MedicineClass of 2002
Certifications & Licensure
FL State License 2021 - Present
AZ State License 2023 - 2026
TX State License 2005 - 2026
AL State License 2023 - 2025
GA State License 2023 - 2025
LA State License 2023 - 2025
MS State License 2023 - 2025
American Board of Internal Medicine Internal Medicine- American Board of Internal Medicine Medical Oncology
- Join now to see all
Clinical Trials
- Nivolumab and Ipilimumab After Donor Stem Cell Transplant in Treating Patients With High Risk Refractory or Relapsed Acute Myeloid Leukemia or Myelodysplastic Syndrome Start of enrollment: 2018 Oct 11
- 2018-0674 - IL-7 for T-Cell Recovery Post Haplo and CB Transplant - Phase I/II Start of enrollment: 2020 Sep 29
Publications & Presentations
PubMed
- Restrictive Ventilatory Defects Following Hematopoietic Stem Cell Transplant Are Associated With Increased Mortality.Mansour Alkhunaizi, Felipe Soto-Lanza, Cheuk Hong Leung, Neel Bhan, Lara Bashoura
Transplantation and Cellular Therapy. 2025-04-01 - A multi-institutional phase 1 clinical trial exploring upfront multimodal standard of care and combined immunotherapies for newly diagnosed glioblastoma.Patrick Y Wen, Andrea Manzanera, Caroline Duault, Edgar Gonzalez-Kozlova, Lenika Lopez
Neuro-Oncology. 2025-03-22 - Immunological biomarkers of response and resistance to treatment with cabozantinib and nivolumab in recurrent endometrial cancer.Vladimir Roudko, Diane Marie Del Valle, Emir Radkevich, Geoffrey Kelly, Xie Hui
Journal for Immunotherapy of Cancer. 2025-02-25
Press Mentions
Developing Novel Therapies Targeting the Tumor Microenvironment of Aggressive Breast CancerApril 3rd, 2025
Grant Support
- MD Anderson Cancer Immune Monitoring and Analysis Center MDA-CIMACUNIVERSITY OF TX MD ANDERSON CAN CTR2017–2028
- MD Anderson Cancer Immune Monitoring and Analysis Center MDA-CIMACUNIVERSITY OF TX MD ANDERSON CAN CTR2017–2028
- Enhancing CAR T Cell Homing Through GlycoengineeringUNIVERSITY OF TX MD ANDERSON CAN CTR2023–2025
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
